Global Atherosclerosis Partnering Deals and Agreements by the World’s Leading Healthcare Companies 2010 to 2017 – Research and Markets

DUBLIN–()–Research and Markets has announced the addition of the “Global
Atherosclerosis Partnering 2010 to 2017”
report to their

The Global Atherosclerosis Therapy Partnering Terms and Agreements since
2010 report provides understanding and access to partnering deals and
agreements entered into by the world’s leading healthcare companies.

The report provides an analysis of partnering deals. The majority of
deals are discovery or development stage whereby the licensee obtains a
right or an option right to license the licensors technology. These
deals tend to be multicomponent, starting with collaborative R&D, and
commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated
deals terms provides critical insight into the negotiation process in
terms of what you can expect to achieve during the negotiation of terms.
Whilst many smaller companies will be seeking details of the payments
clauses, the devil is in the detail in terms of how payments are
triggered – contract documents provide this insight where press releases
do not.

Global Therapy Partnering Terms and Agreements since 2010 report
provides the reader with the following key

– In-depth understanding of deal trends since 2010

– Access to headline, upfront, milestone and royalty data

– Comprehensive access to multiple deals entered into by the world’s
biopharma companies since 2010

– Insight into key deal terms included in contracts, where disclosed

– Understand the key deal terms companies have agreed in deals

– Undertake due diligence to assess suitability of your proposed deal
terms for partner companies

Key Topics Covered:

Read the full article at…

Leave a Reply

Your email address will not be published. Required fields are marked *